Medivir AB (OSTO:MVIR) Total Equity: kr191.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
50 GF Score
Price kr1.80
GF Value kr1.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB Total Equity?

Medivir AB OSTO:MVIR -1.10% 50 Total Equity is kr191.00 Mil as of Mar. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 50/100 and a GF Value™ of kr1.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Medivir AB's total equity for the quarter that ended in Mar. 2026 was kr191.00 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Medivir AB Total Equity Historical Data

* Premium members only.

The historical data trend for Medivir AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Total Equity Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 281.15 192.79 217.93 115.52 155.22

Medivir AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.60 79.60 65.40 155.22 191.00
OSTO:MVIR
50GF Score
Medivir AB OSTO:MVIR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Medivir AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=197.193-41.978
=155.22

Medivir AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=226-35
=191.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr191.00 Mil mean?
Medivir AB (OSTO:MVIR) has a Total Equity of kr191.00 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Medivir AB and its competitors.
Is Medivir AB's Total Equity too high?
Medivir AB's current Total Equity is kr191.00 Mil. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Total Equity compare to VRTX and REGN?
Medivir AB's Total Equity of kr191.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Medivir AB and its competitors. Medivir AB's current Total Equity is kr191.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Total Equity is kr191.00 Mil. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Total Equity is kr191.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • Total Equity: kr191.00 Mil
  • GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score

Get the complete analysis for OSTO:MVIR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.80
Price
kr1.11
GF Value